Endologix, Inc. is a developer and manufacturer of minimally invasive treatments for aortic disorders. We have over 850 employees and listed on NASDAQ (ELGX). Since launching in the U.S. in 2005, Endologix has experienced average annual growth of 60%+ and was the top performing med tech stock in 2009. The Company's Powerlink® System is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. More than 2 million people in the U.S. have AAA, with 200,000 new cases diagnosed every year. If left untreated, AAAs become increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the U.S.

Irvine, US
Size (employees)
782 (est)+27%
Endologix is headquartered in Irvine, US

Endologix Office Locations

Endologix has offices in Irvine and Rosmalen
Irvine, US (HQ)
2 Musick
Rosmalen, NL
40 Burgemeester Burgerslaan

Endologix Metrics

Endologix Financial Metrics

Revenue (2016)

$192.9 m

Revenue growth (2015-16), %


Gross profit

$123.8 m

Gross profit margin (2016), %


Net income (2016)

($154.7 m)

Market capitalization (28-Apr-2017)

$621.1 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$26.1 m
Endologix's current market capitalization is $621.1 m.
Endologix's revenue was reported to be $192.9 m in FY, 2016 which is a 26% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$132.3 m$147.6 m$153.6 m$192.9 m

Revenue growth, %


Cost of goods sold

$41.8 m$51.8 m$69.1 m

Gross profit

$99.5 m$105.8 m$101.8 m$123.8 m

Gross profit Margin, %


Operating expense total

$109.9 m$134.9 m$154.7 m$218.9 m


($10.4 m)($29.1 m)($52.9 m)($95.1 m)

EBIT margin, %


Interest expense

$321 k$5.7 m$7.5 m$15.8 m

Interest income

$50 k$245 k$175 k$228 k

Income tax expense

$10 k$62 k$9.3 m($498 k)

Net Income

($16.1 m)($32.4 m)($50.4 m)($154.7 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$95.2 m$26.8 m$124.6 m$26.1 m

Accounts Receivable

$310 k$498 k$375 k$1.8 m


$19.6 m$31.3 m$27.9 m$41.2 m

Current Assets

$173.6 m$147.8 m$237.5 m$129.8 m


$7.3 m$25.7 m$23.4 m$23.3 m


$29.1 m$28.9 m$28.7 m$120.7 m

Total Assets

$256.2 m$248.2 m$335.8 m$359.7 m

Accounts Payable

$6.3 m$11 m$17.5 m$13.2 m

Current Liabilities

$67.3 m$29.6 m$50.9 m$44.9 m

Additional Paid-in Capital

$321.8 m$372.6 m$404.5 m$567.8 m

Retained Earnings

($216.1 m)($248.5 m)($298.9 m)($453.6 m)

Total Equity

$103.3 m$112.8 m

Financial Leverage

3.3 x3.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($32.4 m)($50.4 m)($154.7 m)

Depreciation and Amortization

$3.3 m$5.9 m$9.1 m

Accounts Receivable


($12 m)$3.5 m$3.5 m

Accounts Payable

$2.7 m$8.3 m($5.2 m)

Cash From Operating Activities

$50 m($26.3 m)($31.1 m)($74.8 m)

Purchases of PP&E

($13.5 m)($4.2 m)($2.8 m)

Cash From Investing Activities

($43.3 m)$2.9 m($28.5 m)

Cash From Financing Activities

$2.1 m$126.7 m$5.3 m

Interest Paid

$2 m$2 m$6.3 m

Income Taxes Paid

$258 k$124 k$208 k

Endologix Market Value History

Endologix Company Life

You may also be interested in